Compare VIGL & DCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund Inc is a diversified closed-end management investment company. Its investment objectives are to seek high current income and to return at least the Fund's original NAV to holders of record of common shares on or about the termination date.